Lian Zengzhi, Pang Pei, Zhu Yan, Du Wenwen, Zhou Jintao
Department of Pulmonary and Critical Care Medicine, Taicang Affiliated Hospital of Soochow University, Suzhou, China.
Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Front Oncol. 2022 May 5;12:832517. doi: 10.3389/fonc.2022.832517. eCollection 2022.
Mitochondrial fission regulator 2 (MTFR2) belongs to the MTFR1 family, which plays a crucial role in regulating oxidative phosphorylation. Recent studies indicate that it also participates in cancer carcinogenesis and development; however, the clinical significance of MTFR2 in lung adenocarcinoma has not been fully confirmed. Our current study investigated the relationships between clinical characteristics and MTFR2 expression based on The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GSE31210) dataset, and clinical histopathological sample cohort. In addition, Kaplan-Meier and Cox regression analyses were additionally performed to evaluate the association between MTFR2 expression and patient survival. Gene set enrichment analysis (GESA) was conducted to spot possible pathways associated with MTFR2. Moreover, a single-sample GESA (ssGESA) was performed to evaluate the association between MTFR2 expression and immune cell infiltration. Cell colony formation assay, CCK-8 assay, cell cycle assay, and transwell assay were performed to verify the cell proliferation, migration, and invasion abilities after interfering with MTFR2 in lung cancer cells. Western blot assay was applied to identify the underlying protein levels. The results indicated that the elevated MTFR2 expression in lung adenocarcinoma samples correlated with T stage ( < 0.001), N stage ( = 0.005), M stage ( = 0.015), pathological stage ( = 0.002), and TP53 status ( < 0.001). Patients with a higher MTFR2 expression correlated with poorer overall survival ( < 0.01) and progression-free survival ( = 0.002). Knockdown of MTFR2 inhibited cell proliferation, migration, and invasion AKT-cyclin D1 signaling and EMT pathways. Moreover, MTFR2 expression significantly positively correlated with Th2 cells ( < 0.001). Taken together, MTFR2 could serve as a novel prognostic indicator and therapeutic target for lung adenocarcinoma.
线粒体裂变调节因子2(MTFR2)属于MTFR1家族,在调节氧化磷酸化过程中起关键作用。近期研究表明,它也参与癌症的发生和发展;然而,MTFR2在肺腺癌中的临床意义尚未得到充分证实。我们目前的研究基于癌症基因组图谱(TCGA)、基因表达综合数据库(GSE31210)数据集以及临床组织病理学样本队列,研究了临床特征与MTFR2表达之间的关系。此外,还进行了Kaplan-Meier和Cox回归分析,以评估MTFR2表达与患者生存之间的关联。进行基因集富集分析(GESA)以发现与MTFR2相关的可能通路。此外,进行单样本GESA(ssGESA)以评估MTFR2表达与免疫细胞浸润之间的关联。进行细胞集落形成试验、CCK-8试验、细胞周期试验和Transwell试验,以验证干扰肺癌细胞中MTFR2后的细胞增殖、迁移和侵袭能力。应用蛋白质免疫印迹法检测相关蛋白水平。结果表明,肺腺癌样本中MTFR2表达升高与T分期(<0.001)、N分期(=0.005)、M分期(=0.015)、病理分期(=0.002)和TP53状态(<0.001)相关。MTFR2表达较高的患者总生存期(<0.01)和无进展生存期(=0.002)较差。敲低MTFR2可抑制细胞增殖、迁移和侵袭,以及AKT-细胞周期蛋白D1信号通路和上皮-间质转化(EMT)通路。此外,MTFR2表达与Th2细胞显著正相关(<0.001)。综上所述,MTFR2可作为肺腺癌的一种新的预后指标和治疗靶点。